AMPH

#2482
Amphastar Pharmaceuticals, Inc.
21.4100 USD
+0.14%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
21.3750
21.4300
Rango anual
17.0300
29.5200
Cambio diario
+0.14%
Variación mensual
+13.10%
Variación en los últimos 6 meses
-12.18%
Cambio anual
-12.18%
Cierres anteriores
21.3800
Abrir
21.3750
Bid
Ask
Mínimo
21.3750
High
21.4300
Volumen
32
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 971.3754 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
13.19
Relación precio/flujo de caja
1.79

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

Noticias